18 March 2024
Kanabo Group
Plc
("Kanabo", the "Group" or the "Company")
Agritec, Marks Milestone in the Medical
Cannabis Project
Pursuant to its announcement on 17 July 2023,
Kanabo Group plc (LSE: KNB) announces that its partially owned
subsidiary, Kanabo Agritec Ltd. ("Agritec"), has now received an
advance payment of over EUR 200,000 from its contract with Taima.
Agritec is providing consulting services and equipment and expects
a further payment of an equal amount upon completion of Phase 1,
totalling over EUR 500,000 in revenue for
Agritec.
Agritec provides consulting services for
facility planning, design, and implementation to produce medical
cannabis. Its expertise includes choosing genetics, automating
irrigation and fertigation, installing humidity control systems,
and optimising harvest through bespoke solutions.
Taima was incorporated as an SPV (special
purpose vehicle) in 2019 and is seeking to establish a network of
facilities for the cultivation and distribution of medical-grade
cannabis in Spain. Notably, partners from Aurea Capital Partners, a
Spanish investment firm focusing on renewable energy and
sustainable agriculture, are invested in the project. Agritec
currently holds 5% of Taima's issued share capital, and its
shareholding will incrementally increase up to 20% based on the
achievement of specific milestones.
Avihu Tamir,
Kanabo Group Plc CEO:
"I am encouraged by the progress of Agritec's
first venture and our strategic collaboration with Taima. This
strategy is integral to our expansion, especially as we leverage
our established distribution channels in the UK. This initiative is
a significant step towards enhancing our supply chain and producing
high-quality medical cannabis products. It prioritises quality and
competitive pricing, enabling scalable growth. Our focus on these
areas, combined with Agritec's expertise, makes Kanabo Group a
long-term player with a built-in advantage in the
industry."
The
Project
The project is running in two stages, with
Phase 1 currently underway. Following completion of Phase 1, the
Spanish Agency of Medicines and Medical Devices ("AEMPS") will
inspect the facility and will grant a license for the production
and manufacturing of medical cannabis and its products, subject to
the successful passing of the inspection.
Upon receipt of the licence, the directors of
Kanabo believe that Agritec will implement Phase 2 of the project,
which Agritec expects to last between 8 and 12 months. At the
conclusion of Phase 2, the facility will be fully operational and
capable of producing up to 3,000 kg of cannabis flowers
annually.
Enquiries:
Kanabo Group
plc
Avihu Tamir, Chief Executive Officer
Assaf Vardimon, Chief Financial
Officer
Ian Mattioli, Non-Executive Chair of the
Board
|
via Vigo Consulting
+44 (0)20 7390 0230
|
Peterhouse
Capital Limited (Financial Adviser and Broker)
Eran Zucker /
Lucy Williams / Charles
Goodfellow
|
+44 (0)20 7469 0930
|
Vigo
Consulting (Financial Public Relations/Investor
Relations)
Jeremy Garcia / Fiona Hetherington / Verity
Snow
kanabo@vigoconsulting.com
|
+44 (0)20 7390 0230
|
About Kanabo
Group plc
Kanabo Group plc (LSE:KNB) is a
digital health company committed to transforming patient care
through its innovative technology platform and specialised
treatment offerings. Since its inception, Kanabo has been focused
on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation
devices.
Kanabo's NHS-approved online
telehealth platform, The GP Service, provides patients with video
consultations, online prescriptions, and primary care services.
Leveraging its telehealth capabilities, Kanabo launched Treat It,
an online clinic focused on chronic pain management that provides
patients with secondary care.
With its two complementary business
divisions, Kanabo has established itself as an end-to-end digital
health provider, offering telehealth consultations and
prescriptions alongside the delivery of tailored
treatments.
The Company's partially owned
subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy
supporting cannabis businesses in developing new farms through
infrastructural, research, and product guidance. These farms
deliver high-quality raw materials for Kanabo's formulas and
product line.
At Kanabo Group Plc, we are dedicated
to providing patients with the highest quality medical treatments
and more accessible healthcare experiences.
Visit www.kanabogroup.com for
more information.